Total raised
—
Last: Undisclosed 2023-01
Stage
Seed
Founded
2016
Headcount
10
HQ
Netanya
Sector
Health Tech & Life Sciences
About
4C Biomed combines cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the research and development of immuno-oncology therapies. Its lead drug is an IND-ready asset and is planned to enter clinical Phase I in 2026.
4C Biomed’s technology leverages a uniquely sensitive, immunological-based screening platform, which not only identifies novel immuno-oncology targets but also promises to accelerate the journey from discovery to clinical application.
Funding history · 1 round · — total
2023-01
Undisclosed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancer-therapyoncologyimmunotherapyimmunologydrug-discoverycancerdrug-developmentpharmaceuticals